Skip to main content

Tag: German cultivation bid

German Cultivation Bids Reverberate Across the Global Cannabis Industry

The day after the third annual International Cannabis Business Conference in Berlin, as the crew packed up and headed on to Zurich, news about the German cultivation bid surfaced in the domestic media. Namely, that three bid finalists (Aurora, Aphria and Demecan, a start-up founded with Wayland) had been selected. This is unofficial “news” as not only does the bid process itself face a pending lawsuit that is headed to court in Germany this week, but insiders on the ground in Germany will also not be surprised to see more legal action challenging this decision. So far, BfArM, the federal agency managing the bid has yet to make an official announcement.

Regardless, even the “unofficial” news is a sign that the German market is starting to gain not only traction but formal shape (starting with established pricing).

In the meantime, International Cannabis Business Conference Berlin saw producers from all over the world descend on a cannabis industry gathering that has already earned its stripes if not its rightful moniker as the “Cannes of Cannabis.” Dealmakers came together in Berlin from Australia, Israel, Canada, many countries in Latin America and several from the African continent to sell to Europe and an opening market. As one Australian producer said “there was more demand here than we could possibly fill.”

In fact, several weeks before the International Cannabis Business Conference, signs were already afoot that the market is opening for international competition from all over the world – not just Canada and Holland, as has been the case up until now. Frankfurt based Farmeko announced a 50 tonne, four-year import deal from Macedonia via Poland in mid March.

The biggest news about the bid, however, is not that it seems to be at least resolving for this first round but that other opportunities are opening in its wake – and not only in Germany but across the continent.

Greece is fully engaging the licensing process, it is very likely that Poland may start down the cultivation path soon and the UK and Ireland are all moving questions at this point.

Switzerland, of course, represents another unique wrinkle in all of this and may prove yet to be the market leader in Europe on the recreational front for several reasons – namely it is not an EU member but part of the economic framework of the region.

The combination, however, clearly of all of these fragmented puzzle pieces moving forward, surrounding the activity around the German bid is absolutely one of the strongest catalysts for the entire conversation. Not to mention a conference now in its third year that brings all the movers and shakers together in one place.

This spring, in other words, is a critical building year for the industry across the continent and the International Cannabis Business Conference is right in the middle of the conversation.

It is not too late to book your tickets for the International Cannabis Business Conference’s first year in Zurich, a megaconference team-up with CannaTrade! Early-bird prices end on April 24th.

First German Cannabis Cultivation Bids Announced!

The German medical cannabis system has been an innovative pioneer in a few respects, helping thousands of patients get access to tested medicinal cannabis that is covered by their insurance programs. However, regulatory burdens and the lack of domestic cultivation have hindered the program, increasing prices and decreasing the availability of strains and products. The German government has been accepting domestic cultivation applications in a process that has been complicated and shrouded in secrecy. Applicants could not even speak about applying or their bid would be hindered, as was discussed at the recent International Cannabis Business Conference in Berlin. Last week, Germany took a big step forward announcing three companies that have been selected for licenses, pending some issues still left to be worked out.

Our good friends at the German Cannabis Association (DHV) informed their supporters of this historic news in a newsletter (slight editing done due to Google translation issues):

One day after the International Cannabis Business Conference a message came in, with the judge not before 10:04. had expected. On Wednesday, the Federal Institute for Drugs and Medical Devices (BfArM) informed the 79 candidates who had applied for the cultivation of medicinal purposes in Germany. Accordingly, three companies, including the Canadian producer Aurora and Aphria and the German company Demecan should, (produce) the first medical cannabis in Germany grow(n). Originally, the Düsseldorf Higher Regional Court should adjudicate on an application that ran against the second licensing round on 04.10.2019. Given the ever-increasing numbers of patients but also advertised by the Cannabis Agency amount will not be enough and Germany will continue to be dependent on imports of medicinal purposes. Other licensing agreements are inevitable to meet as a medicine the increasing demand for cannabis from the perspective of the German Cannabis Association.

The sooner that domestic cultivation can occur, the better it will be for patients. The competition should be good for patients as Marguerite Arnold wrote for the Cannabis Industry Journal, importing into the country is also increasing, so prices should drop:

Several weeks ago, a Frankfurt-based distribution start-up announced that they had successfully imported cannabis into the country from Macedonian-based Nysk Holdings via Poland.

At the International Cannabis Business Conference in Berlin last weekend, Australian producers (for one) were also reporting a German demand for their product that was greater than they could fill. And there were many Israelis present for what is expected to be an official opening of their import ability by the third quarter of this year.

The bid itself is going to have a powerful impact on pricing in both the German and European market beyond that. It represents the first time in any country that a government has attempted to pre-negotiate prices for the drug as a narcotic beyond Israel and in this case, it will have at least regional implications.

While there are gonna be some more ups and downs, including lawsuits and bureaucratic wrangling, but Germany moving forward with domestic cultivation licenses is a great step forward for patients and the German cannabis industry. What happens in Germany ripples across the European continent and beyond, and you can learn the latest about these bids and the greater European industry at the next International Cannabis Business Conference in Zurich, Switzerland, this May 15th-16th, in collaboration with CannaTrade (taking place the 17th-19th), get your early-bird tickets by April 24th to save.